Company

CEO COMPANY

HysensBio History

    • 1999

    • · Began scientific research on dentin regeneration

    • 2016

    • · Confirmed regenerative function of dentin regenerative protein
    • · Established HysensBio Co., Ltd.
    • · Certified as venture company

    • 2017

    • · Established Corporate R&D Center
    • · Developed the novel KH001 functional peptide
    • · Funded by Korean Ministry of Commerce Industry & Energy (KRW 2B)

    • 2018

    • · Series A Funding(KRW 2B)

    • 2019

    • · Series B Funding(KRW 7B)
    • · New Technology Award, Ministry of Commerce Industry & Energy (Nov 2019)

    • 2020

    • · Grand prize in Creative Innovation of 50+ Awards, LINA Korea
    • · Selected as Potential Unicorn Corporate by Ministry of SMEs & Startups
    • · KH001 Phase 1/2a IND Approval (Korea)

    • 2021

    • · Series C Funding

    • 2022

    • · IR52 Jang Young-shil Award, Ministry of Science & ICT
    • · Established JV with Orion Holdings and out-licensing to Orion Biologics

    • 2023

    • · KH-001(Dentin Hypersensitivity) Phase 1/2a Completed
    • · SI / Pre-IPO Funding
    • · Biohealth R&D Best Company Award, Ministry of Trade, Industry & Energy

    • 2024

    • · KH-001(Dentin Hypersensitivity) Phase 2:
         Completed in Korea, Ongoing in the USA
    • · KH-002(Dental Caries) IIT in progress
    • · HB-901(Veterinary Dental Medicine) Evaluation License Agreement signed with Merck Animal Health
    • · HBO-001(Amelogenesis Imperfecta): U.S. FDA Orphan Drug Designation Granted